LAM RESEARCH CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LAM RESEARCH CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Jun 26, 2011 | $3.24B | Aug 19, 2011 |
| FY2011 | Jun 27, 2010 | $2.13B | Aug 19, 2011 |
| FY2011 | Jun 28, 2009 | $1.12B | Aug 19, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $18.44B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $14.91B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $17.43B | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $17.23B | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $14.63B | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $10.04B | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $9.65B | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $11.08B | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $8.01B | Aug 20, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 24, 2018 | $11.08B | Aug 14, 2018 |
| FY2018 | Jun 25, 2017 | $8.01B | Aug 14, 2018 |
| FY2018 | Jun 26, 2016 | $5.89B | Aug 14, 2018 |
| FY2017 | Jun 28, 2015 | $5.26B | Aug 15, 2017 |
| FY2016 | Jun 29, 2014 | $4.61B | Aug 17, 2016 |
| FY2015 | Jun 30, 2013 | $3.60B | Aug 13, 2015 |
| FY2014 | Jun 24, 2012 | $2.67B | Aug 26, 2014 |
| FY2013 | Jun 26, 2011 | $3.24B | Aug 27, 2013 |
| FY2012 | Jun 27, 2010 | $2.13B | Aug 22, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $8.98B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $7.05B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $7.78B | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $7.87B | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $6.81B | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $4.61B | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $4.36B | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $5.17B | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $3.60B | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | $2.62B | Aug 14, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $5.36B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $3.83B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $4.51B | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $4.61B | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $3.91B | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $2.25B | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $2.19B | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $2.38B | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $1.70B | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | $914.05M | Aug 14, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $5.90B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $4.26B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $5.17B | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $5.38B | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $4.48B | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $2.67B | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $2.46B | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $3.21B | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $1.90B | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | $1.07B | Aug 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $2.10B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $1.90B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $1.73B | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $1.60B | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $1.49B | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $1.25B | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $1.19B | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $1.19B | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $1.03B | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | $913.71M | Aug 14, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $981.70M | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $868.25M | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $832.75M | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $885.74M | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $829.88M | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $682.48M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $702.41M | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $762.22M | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $667.49M | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | $630.95M | Aug 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $6.17B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $4.65B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $5.18B | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $3.10B | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $3.59B | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $2.13B | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $3.18B | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $2.66B | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $2.03B | Aug 20, 2019 |
| FY2013 | Jun 30, 2013 | $719.93M | Aug 27, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $21.35B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $18.74B | Aug 11, 2025 |
| FY2024 | Jun 25, 2023 | $18.78B | Aug 29, 2024 |
| FY2023 | Jun 26, 2022 | $17.20B | Aug 15, 2023 |
| FY2022 | Jun 27, 2021 | $15.89B | Aug 24, 2022 |
| FY2021 | Jun 28, 2020 | $14.56B | Aug 17, 2021 |
| FY2020 | Jun 30, 2019 | $12.00B | Aug 18, 2020 |
| FY2019 | Jun 25, 2018 | $12.49B | Aug 20, 2019 |
| FY2019 | Jun 24, 2018 | $12.48B | Aug 20, 2019 |
| FY2018 | Jun 25, 2017 | $12.12B | Aug 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $11.48B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $10.21B | Aug 11, 2025 |
| FY2024 | Jun 25, 2023 | $10.57B | Aug 29, 2024 |
| FY2023 | Jun 26, 2022 | $10.92B | Aug 15, 2023 |
| FY2022 | Jun 27, 2021 | $9.86B | Aug 24, 2022 |
| FY2021 | Jun 28, 2020 | $9.38B | Aug 17, 2021 |
| FY2020 | Jun 30, 2019 | $7.28B | Aug 18, 2020 |
| FY2019 | Jun 25, 2018 | $5.77B | Aug 20, 2019 |
| FY2019 | Jun 24, 2018 | $5.90B | Aug 20, 2019 |
| FY2018 | Jun 25, 2017 | $5.14B | Aug 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $9.86B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $8.54B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $8.21B | Aug 11, 2025 |
| FY2025 | Jun 26, 2022 | $6.28B | Aug 11, 2025 |
| FY2024 | Jun 27, 2021 | $6.03B | Aug 29, 2024 |
| FY2023 | Jun 28, 2020 | $5.17B | Aug 15, 2023 |
| FY2022 | Jun 30, 2019 | $4.67B | Aug 24, 2022 |
| FY2019 | Jun 25, 2018 | $6.64B | Aug 20, 2019 |
| FY2021 | Jun 24, 2018 | $6.50B | Aug 17, 2021 |
| FY2020 | Jun 25, 2017 | $6.82B | Aug 18, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $1.60B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $1.60B | Aug 11, 2025 |
| FY2024 | Jun 25, 2023 | $1.62B | Aug 29, 2024 |
| FY2023 | Jun 26, 2022 | $1.52B | Aug 15, 2023 |
| FY2022 | Jun 27, 2021 | $1.49B | Aug 24, 2022 |
| FY2021 | Jun 28, 2020 | $1.48B | Aug 17, 2021 |
| FY2020 | Jun 30, 2019 | $1.48B | Aug 18, 2020 |
| FY2019 | Jun 24, 2018 | $1.48B | Aug 20, 2019 |
| FY2019 | Aug 28, 2017 | $98.92M | Aug 20, 2019 |
| FY2018 | Jun 25, 2017 | $1.39B | Aug 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $28.99B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $24.81B | Aug 11, 2025 |
| FY2024 | Jun 25, 2023 | $22.03B | Aug 29, 2024 |
| FY2023 | Jun 26, 2022 | $18.45B | Aug 15, 2023 |
| FY2022 | Jun 27, 2021 | $14.68B | Aug 24, 2022 |
| FY2021 | Jun 28, 2020 | $11.52B | Aug 17, 2021 |
| FY2020 | Jun 30, 2019 | $9.93B | Aug 18, 2020 |
| FY2019 | Jun 24, 2018 | $8.26B | Aug 20, 2019 |
| FY2018 | Jun 25, 2017 | $6.25B | Aug 14, 2018 |
| FY2017 | Jun 26, 2016 | $4.82B | Aug 15, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $6.39B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $5.85B | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | $5.34B | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | $3.52B | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | $4.42B | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | $4.92B | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $3.66B | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | $4.51B | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | $2.38B | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | $5.04B | Aug 14, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | $4.47B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | $4.97B | Aug 11, 2025 |
| FY2024 | Jun 25, 2023 | $4.97B | Aug 29, 2024 |
| FY2023 | Jun 26, 2022 | $4.96B | Aug 15, 2023 |
| FY2022 | Jun 27, 2021 | $4.96B | Aug 24, 2022 |
| FY2021 | Jun 28, 2020 | $5.80B | Aug 17, 2021 |
| FY2020 | Jun 30, 2019 | $4.43B | Aug 18, 2020 |
| FY2019 | Jun 24, 2018 | $2.37B | Aug 20, 2019 |
| FY2018 | Jun 25, 2017 | $2.69B | Aug 14, 2018 |
| FY2017 | Jun 26, 2016 | $4.32B | Aug 15, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | 4 | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | 2 | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | 3 | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | 32 | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | 27 | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | 15 | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | 14 | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | 14 | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | 10 | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | 5 | Aug 14, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | 4 | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | 2 | Aug 11, 2025 |
| FY2025 | Jun 25, 2023 | 3 | Aug 11, 2025 |
| FY2024 | Jun 26, 2022 | 32 | Aug 29, 2024 |
| FY2023 | Jun 27, 2021 | 26 | Aug 15, 2023 |
| FY2022 | Jun 28, 2020 | 15 | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | 13 | Aug 17, 2021 |
| FY2020 | Jun 24, 2018 | 13 | Aug 18, 2020 |
| FY2019 | Jun 25, 2017 | 9 | Aug 20, 2019 |
| FY2018 | Jun 26, 2016 | 5 | Aug 14, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 29, 2025 | 1.27B | Aug 11, 2025 |
| FY2025 | Jun 30, 2024 | 1.30B | Aug 11, 2025 |
| FY2024 | Jun 25, 2023 | 133.30M | Aug 29, 2024 |
| FY2023 | Jun 26, 2022 | 136.98M | Aug 15, 2023 |
| FY2022 | Jun 27, 2021 | 142.50M | Aug 24, 2022 |
| FY2021 | Jun 28, 2020 | 145.33M | Aug 17, 2021 |
| FY2020 | Jun 30, 2019 | 144.43M | Aug 18, 2020 |
| FY2019 | Jun 24, 2018 | 156.89M | Aug 20, 2019 |
| FY2018 | Jun 25, 2017 | 161.72M | Aug 14, 2018 |
| FY2017 | Jun 26, 2016 | 160.20M | Aug 15, 2017 |